OrthoPediatrics Files 8-K on Operations & Financial Condition

Ticker: KIDS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1425450

Orthopediatrics Corp 8-K Filing Summary
FieldDetail
CompanyOrthopediatrics Corp (KIDS)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.00025
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, financial-condition, operations, 8-K

TL;DR

**OrthoPediatrics (KIDS) filed an 8-K, a standard update on its financial and operational status.**

AI Summary

OrthoPediatrics Corp. filed an 8-K on January 8, 2024, to report on its financial condition and operations, specifically regarding the date of an earliest event reported on January 8, 2024. This filing indicates that the company, trading under the symbol KIDS on the Nasdaq Global Market, is providing an update on its business activities. For investors, this matters because it signals that the company is adhering to SEC disclosure requirements, providing transparency into its ongoing financial health and operational status, which can influence stock valuation.

Why It Matters

This filing provides a routine update on OrthoPediatrics' business, ensuring investors have current information about the company's financial and operational status, which is crucial for informed decision-making.

Risk Assessment

Risk Level: low — This is a routine disclosure filing (8-K) without any specific negative events or significant changes mentioned, indicating a low immediate risk.

Analyst Insight

This filing is a routine disclosure and does not contain new material information that would warrant immediate action. Investors should continue to monitor future filings for substantive updates on financial performance or strategic changes.

Key Numbers

  • 001-38242 — Commission File Number (identifies the company's registration with the SEC)
  • 26-1761833 — I.R.S. Employer Identification Number (identifies the company for tax purposes)
  • 574-268-6379 — Registrant’s telephone number (contact information for the company)
  • 2850 Frontier Drive, Warsaw, Indiana 46582 — Address of principal executive offices (physical location of the company's headquarters)

Key Players & Entities

  • OrthoPediatrics Corp. (company) — the registrant filing the 8-K
  • Nasdaq Global Market (company) — the exchange where OrthoPediatrics' common stock is registered
  • KIDS (company) — the trading symbol for OrthoPediatrics Corp.
  • January 8, 2024 (date) — the date of the earliest event reported and the filing date
  • $0.00025 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

  • OrthoPediatrics will continue to file routine disclosures as required by the SEC. (OrthoPediatrics Corp.) — high confidence, target: 2024-12-31

FAQ

What is the purpose of this 8-K filing by OrthoPediatrics Corp.?

The 8-K filing by OrthoPediatrics Corp. is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically reporting on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' as of January 8, 2024.

What is the trading symbol and exchange for OrthoPediatrics Corp. common stock?

The Common Stock, with a par value of $0.00025 per share, of OrthoPediatrics Corp. trades under the symbol 'KIDS' on the Nasdaq Global Market.

Is OrthoPediatrics Corp. considered an 'emerging growth company'?

Yes, OrthoPediatrics Corp. has indicated by check mark that it is an 'emerging growth company' as defined in Rule 405 under the Securities Act or Rule 12b-2 under the Exchange Act.

What is the earliest event reported date in this 8-K filing?

The 'Date of Report (Date of earliest event reported)' for this 8-K filing is January 8, 2024.

What are the specific items of information included in this 8-K filing?

The specific items of information included in this 8-K filing are 'Results of Operations and Financial Condition', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.

Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-01-08 08:18:12

Key Financial Figures

  • $0.00025 — ange on which registered Common Stock, $0.00025 par value per share KIDS Nasdaq Global

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, OrthoPediatrics Corp. (the "Company") issued a press release announcing its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023, providing management's projection of 2024 net revenue and providing a related business update. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The financial information set forth in this Form 8-K reflects the Company's current preliminary net revenue estimates, is subject to the completion of its audit process, and is subject to change. The Company's fourth quarter and full year ended December 31, 2023 results could differ materially from the preliminary estimates provided in this form 8-K. The Company's net revenue for the full year ended December 31, 2024 could also differ materially from the forecasted amounts. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. You should refer to the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 1, 2023, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results and net revenue to differ materially from those expressed or implied by these forward-looking statements. Given th

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.2 herewith, in whole or in part, as part of those presentations. The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.2, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 8, 2024 99.2 Orthopediatrics Corp. Investor Presentation dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * * * * * * - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OrthoPediatrics Corp. Date: January 8, 2024 By: /s/ Daniel J. Gerritzen Daniel J. Gerritzen, General Counsel and Secretary - 3 -

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.